Last updated on January 2020

Study of Nivolumab Plus Ipilimumab Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer | Malignant neoplasm of prostate | Recurrent | Early | Prostate Disorders | Prostatic disorder
  • Age: Between 18 - 100 Years
  • Gender: Male

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

  • Evidence of Stage IV disease (as defined by American Joint Committee of Cancer criteria) on previous bone, CT and/or MRI scan.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone (GnRH) analogue or a surgical/medical castration with testosterone level of 1.73nmol/L (50ng/dL)
  • Participants with skeletal system symptoms who are already on medications to strengthen bones are allowed if they were started 28 days before study treatment

Exclusion Criteria:

  • Cancer that has spread to the liver or brain
  • Active, known, or suspected autoimmune disease or infection
  • Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
  • Prior whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow. Bone-directed radiotherapy for palliation of painful bone metastases to pelvic region is allowed up to 14 days before treatment assignment.

Other protocol defined inclusion/exclusion criteria could apply

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.